Imetelstat for Myelodysplastic Syndrome
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this clinical trial is to learn if imetelstat is safe to use in participants with high-risk myeloid malignancies who have received an allogenic hematologic stem cell transplantation (allo-SCT).
Participants will receive imetelstat by intravenous infusion once every 28 days for up to one year.
Who Is on the Research Team?
Hongtao Liu, MD, PhD
Principal Investigator
University of Wisconsin, Madison
Are You a Good Fit for This Trial?
This trial is for people with high-risk blood cancers like leukemia or myelofibrosis who have already had a stem cell transplant from a donor. Participants should be healthy enough after their transplant to receive further treatment.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- imetelstat
Trial Overview
The study is testing the safety of imetelstat, given by IV once every 28 days for up to one year, as ongoing (maintenance) therapy after a donor stem cell transplant in patients with certain high-risk blood cancers.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants will receive imetelstat intravenously every 4 weeks with dose escalation.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Wisconsin, Madison
Lead Sponsor
Geron Corporation
Industry Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.